What is Mapi Pharma?
Mapi Pharma is a clinical-stage pharmaceutical company headquartered in Ness Ziona, Israel, established in 2008. The company specializes in the development of advanced long-acting depot injectable treatments and complex active pharmaceutical ingredients. Its lead product candidate, Glatiramer Acetate Depot, is intended for the treatment of multiple sclerosis, addressing a substantial market need. Mapi Pharma also has a pipeline including extended-release Pregabalin for neuropathic pain and treatments for schizophrenia. The company operates integrated GMP manufacturing facilities, supporting its development and production capabilities.
How much funding has Mapi Pharma raised?
Mapi Pharma has raised a total of $10M across 1 funding round:
Share Placement
$10M
Share Placement (2015): $10M with participation from Shavit Capital
Key Investors in Mapi Pharma
Shavit Capital
Shavit Capital is a private equity firm that specializes in late-stage investments in Israeli and Israeli-related companies, focusing on equity mezzanine or bridge rounds for companies nearing an IPO. They manage over $500 million and target companies with proven technologies and strong management.
What's next for Mapi Pharma?
With the recent major strategic investment, Mapi Pharma is poised to accelerate the development and commercialization of its product pipeline. The enterprise-level capital infusion will likely support further clinical trials, regulatory submissions, and the scaling of its manufacturing operations. This strategic backing signals confidence in Mapi Pharma's innovative therapeutic approach and its potential to capture significant market share in its target indications, particularly in the multiple sclerosis and neuropathic pain segments.
See full Mapi Pharma company page
